Blood, Blood Components, Plasma, and Plasma Products

Perner, 2015, Scandinavian clinical practice guidelines on choice of fluid resuscitation of critically ill patients with acute circulatory failure, Acta Anaesthesiol Scand, 59, 274, 10.1111/aas.12429 Caironi, 2015, Albumin in critically ill patients: the ideal colloid?, Curr Opin Crit Care, 21, 302, 10.1097/MCC.0000000000000223 Das, 2015, Albumin infusion for the critically ill—is it beneficial and if so why and how?, Crit Care, 19, 156, 10.1186/s13054-015-0862-4 Ginsberg, 2015, Symptomatic intracranial hemorrhage in the ALIAS multicenter trial: relationship to endovascular thrombolytic therapy, Int J Stroke, 10, 494, 10.1111/ijs.12476 Pathirana, 2015, The effects of hemodilution with albumin on coagulation in vitro as assessed by rotation thromboelastometry, Anaesth Intensive Care, 43, 187, 10.1177/0310057X1504300207 Opperer, 2015, Use of perioperative hydroxyethyl starch 6% and albumin 5% in elective joint arthroplasty and association with adverse outcomes: retrospective population based analysis, BMJ, 350, h1567, 10.1136/bmj.h1567 Garcia-Martinez, 2015, Albumin infusion improves renal blood flow autoregulation in patients with acute decompensation of cirrhosis and acute kidney injury, Liver Int, 35, 335, 10.1111/liv.12528 Thevenot, 2015, Effect of albumin in cirrhotic patients with infection other that spontaneous bacterial peritonitis, a randomized trial, J Hepatol, 62, 822, 10.1016/j.jhep.2014.11.017 Ertmer, 2015, Impact of human albumin infusion on organ function in orthotopic liver transplantation—a retrospective matched-pair analysis, Clin Transplant, 29, 67, 10.1111/ctr.12486 Jonhson, 2015, Reduced albumin dosing during large-volume paracentesis is not associated with adverse clinical outcomes, Dig Dis Sci, 60, 2190, 10.1007/s10620-015-3578-z Tatlow, 2015, Novel method for rapid reversal of drug toxicity: a case report, Clin Exp Pharmacol Physiol, 42, 389, 10.1111/1440-1681.12358 Muller, 2015, Transfusion of packed red cells: indications, triggers and adverse events, Dtsch Arztebl Int, 112, 507 Harvey, 2015, Transfusion-related adverse reactions reported to the National Healthcare Safety Network Hemovigilance Module, United States, 2010 to 2012, Transfusion, 55, 709, 10.1111/trf.12918 Rogers, 2016, Haemovigilance of reactions associated with red blood cell transfusion: comparison across 17 countries, Vox Sang, 110, 266, 10.1111/vox.12367 Clifford, 2015, Characterizing the epidemiology of postoperative transfusion-related acute lung injury, Anesthesiology, 122, 12, 10.1097/ALN.0000000000000514 Mulder, 2015, Incidence, risk factors, and outcome of transfusion-related acute lung injury in critically ill children: a retrospective study, J Crit Care, 30, 55, 10.1016/j.jcrc.2014.10.005 Likosky, 2015, Red blood cell transfusions impact pneumonia rates after coronary artery bypass grafting, Ann Thorac Surg, 100, 794, 10.1016/j.athoracsur.2015.03.089 Mariscalco, 2015, Red blood cell transfusion is a determinant of neurological complications after cardiac surgery, Interact Cardiovasc Thorac Surg, 20, 166, 10.1093/icvts/ivu360 Raza, 2015, A prospective study on red blood cell transfusion related hyperkalemia in critically ill patients, J Clin Med Res, 7, 417, 10.14740/jocmr2123w Clifford, 2015, Characterizing the epidemiology of perioperative transfusion-associated circulatory overload, Anesthesiology, 122, 21, 10.1097/ALN.0000000000000513 Vidler, 2015, Delayed haemolytic transfusion reaction in adults with sickle cell disease: a 5-year experience, Br J Haematol, 169, 746, 10.1111/bjh.13339 L’Acqua, 2015, Red blood cell transfusion is associated with increased hemolysis and an acute phase response in a subset of critically ill children, Am J Hematol, 90, 915, 10.1002/ajh.24119 Kopolovic, 2015, A systematic review of transfusion-associated graft-versus-host disease, Blood, 126, 406, 10.1182/blood-2015-01-620872 Brunskill, 2015, Red blood cell transfusion for people undergoing hip fracture surgery, Cochrane Database Syst Rev, 4, CD009699 Fabricius, 2016, Effect of transfusion strategy in acute non-variceal upper gastrointestinal bleeding: a nationwide study of 5861 hospital admissions in Denmark, World J Surg, 40, 1129, 10.1007/s00268-015-3370-4 Ng, 2015, Effects of packed red blood cell storage duration on post-transfusion clinical outcomes: a meta-analysis and systematic review, Intensive Care Med, 41, 2087, 10.1007/s00134-015-4078-5 Yamal, 2015, Association of transfusion red blood cell storage age and blood oxygenation, long-term neurologic outcome, and mortality in traumatic brain injury, J Trauma Acute Care Surg, 79, 843, 10.1097/TA.0000000000000834 Kato, 2015, A retrospective observational study to assess adverse transfusion reactions of patients with and without prior transfusion history, Vox Sang, 108, 243, 10.1111/vox.12208 Estcourt, 2015, Granulocyte transfusions for preventing infections in people with neutropenia or neutrophil dysfunction, Cochrane Database Syst Rev, 6, CD005341 Marfin, 2015, Granulocyte transfusion therapy, J Intensive Care Med, 30, 79, 10.1177/0885066613498045 Kadri, 2015, Role of granulocyte transfusions in invasive fusariosis: systematic review and single-center experience, Transfusion, 55, 2076, 10.1111/trf.13099 Ambruso, 2015, Hydroxyethyl starch and granulocyte transfusions: considerations of utility and toxicity profile for patients and donors, Transfusion, 55, 911, 10.1111/trf.12892 Kaufman, 2015, Platelet transfusion: a clinical practice guideline from the AABB, Ann Intern Med, 162, 205, 10.7326/M14-1589 Harvey, 2015, Transfusion-related adverse reactions reported to the National Healthcare Safety Network Hemovigilance Module, United States, 2010 to 2012, Transfusion, 55, 709, 10.1111/trf.12918 Kremke, 2015, The association between platelet transfusion and adverse outcomes after coronary artery bypass surgery, Eur J Cardiothorac Surg, 48, e102, 10.1093/ejcts/ezv297 Crighton, 2014, A therapeutic-only versus prophylactic platelet transfusion strategy for preventing bleeding in patients with haematological disorders after myelosuppressive chemotherapy or stem cell transplantation, Cochrane Database Syst Rev, 9, CD010981 Clifford, 2015, Characterizing the epidemiology of perioperative transfusion-associated circulatory overload, Anesthesiology, 122, 21, 10.1097/ALN.0000000000000513 Kaufman, 2015, Transfusion-related adverse events in the platelet dose study, Transfusion, 55, 144, 10.1111/trf.12791 Knutson, 2015, A prospective, active haemovigilance study with combined cohort analysis of 19,175 transfusions of platelet components prepared with amotosalen-UVA photochemical treatment, Vox Sang, 109, 343, 10.1111/vox.12287 Garraud, 2016, Improving platelet transfusion safety: biomedical and technical considerations, Blood Transfus, 14, 109 Mackenzie, 2015, Are hemoglobin-based oxygen carriers being withheld because of regulatory requirement for equivalence to packed red blood cells?, Am J Ther, 22, e115, 10.1097/MJT.0000000000000009 Njoku, 2015, Haemoglobin-based oxygen carriers: indications and future applications, Br J Hosp Med, 76, 78, 10.12968/hmed.2015.76.2.78 Teschler, 2015, Long-term experience in the treatment of alpha-1 antitrypsin deficiency: 25 years of augmentation therapy, Eur Respir Rev, 24, 46, 10.1183/09059180.10010714 Zuo, 2016, Historical role of alpha-1 antitrypsin in respiratory and hepatic complications, Gene, 16, 6 Zuraw, 2015, Phase II study results of a replacement therapy for hereditary angioedema with subcutaneous C1-inhibitor concentrate, Allergy, 70, 1319, 10.1111/all.12658 Busse, 2015, Safety of C1-esterase inhibitor in acute and prophylactic therapy of hereditary angioedema: findings from the ongoing international Berinert patient registry, J Allergy Clin Immunol Pract, 3, 213, 10.1016/j.jaip.2014.08.014 Li, 2015, Recombinant human-C1 inhibitor is effective and safe for repeat hereditary angioedema attacks, J Allergy Clin Immunol Pract, 3, 417, 10.1016/j.jaip.2014.12.013 Rapid response report, 2015, 1 Riedl, 2015, Recombinant human C1 esterase inhibitor in the management of hereditary angioedema, Clin Drug Investig, 35, 407, 10.1007/s40261-015-0300-z Moldovan, 2015, Recombinant replacement therapy for hereditary angioedema due to C1 inhibitor deficiency, Immunotherapy, 7, 739, 10.2217/imt.15.44 Lumry, 2015, Safety and efficacy of C1 esterase inhibitor for acute attacks in children with hereditary angioedema, Pediatr Allergy Immunol, 26, 674, 10.1111/pai.12444 Nascimento, 2014, Cryoprecipitate therapy, Br J Anaesth, 113, 922, 10.1093/bja/aeu158 Oakley, 2015, Transfusion reactions in pediatric compared with adult patients: a look at rate, reaction type, and associated products, Transfusion, 55, 563, 10.1111/trf.12827 Harvey, 2015, Transfusion-related adverse reactions reported to the National Healthcare Safety Network Hemovigilance Module, United States, 2010 to 2012, Transfusion, 55, 709, 10.1111/trf.12918 Desborough, 2015, Fresh frozen plasma for cardiovascular surgery, Cochrane Database Syst Rev, 7, CD007614 Murphy, 2015, Blood transfusion: summary of NICE guidance, BMJ, 351, h5832, 10.1136/bmj.h5832 Rasmussen, 2015, More complications in patient with septic shock treated with dextran compared to crystalloids, Dan Med J, 62, A5018 Opperer, 2015, Use of perioperative hydroxyethyl starch 6% and albumin 5% in elective joint arthroplasty and association with adverse outcomes: a retrospective population based analysis, BMJ, 30, h1567, 10.1136/bmj.h1567 Hand, 2015, Hydroxyethyl starch and acute kidney injury in orthotopic liver transplantation: a single-center retrospective review, Anesth Analg, 120, 619, 10.1213/ANE.0000000000000374 Blasco, 2015, Long-term outcome in kidney recipients from donors treated with hydroyethylstarch 130/0.4 and hydroxyethylstartch 200/0/6, Br J Anaesth, 115, 798, 10.1093/bja/aev335 Muller, 2015, Acute kidney injury with hydroxyethyl starch 130/0.42 in severe sepsis, Acta Anaesthesiol Scand, 59, 329, 10.1111/aas.12453 Pinholt Kancir, 2015, The effect of 6% hydroxyethyl starch 130/0.4 on renal function, arterial blood pressure and vasoactive hormones during radical prostatectomy: a randomized controlled trial, Anesth Analg, 120, 608, 10.1213/ANE.0000000000000596 Li, 2015, Safety evaluation on low-molecular-weight hydroxyethyl starch for volume expansion therapy in pediatric patients: a meta-analysis of randomized controlled trial, Crit Care, 19, 79, 10.1186/s13054-015-0815-y Van der Linden, 2015, Efficacy and safety of 6% hydroxyethyl starch 130/0.4 for perioperative volume replacement in children undergoing cardiac surgery: a propensity-matched analysis, Crit Care, 19, 87, 10.1186/s13054-015-0830-z Ozturk, 2015, Immune and inflammatory role of hydroxyethyl starch 130/0.4 and fluid gelatin in patients undergoing coronary surgery, Cytokine, 74, 69, 10.1016/j.cyto.2014.10.002 He, 2015, Hydroxyethyl starch versus other fluids for non-septic patients in the intensive care unit: a meta-analysis of randomized controlled trials, Crit Care, 19, 92, 10.1186/s13054-015-0833-9 Agarwal, 2015, Life-threatening intraoperative anaphylaxis to gelatin in Floseal during pediatric spinal surgery, J Allergy Clin Immunol Pract, 3, 110, 10.1016/j.jaip.2014.05.010 Ji, 2015, Suspected intraoperative anaphylaxis to gelatin absorbable hemostatic sponge, Anesth Prog, 62, 22, 10.2344/0003-3006-62.1.22 Wang, 2015, Intravenous immunoglobulin in critically ill adults: when and what is the evidence?, J Crit Care, 30, 652e9, 10.1016/j.jcrc.2015.01.022 Clark, 2015, Safety of intravenous immunoglobulin and plasma exchange in critically ill patients, Neurol Res, 37, 593, 10.1179/1743132815Y.0000000017 Lozeron, 2015, Safety of IVIg in the elderly treated for a dysimmune neuromuscular disease, Muscle Nerve Jain, 2015, Anaphylaxis with intravenous immunoglobulin: a time for introspection, Am J Emerg Med, 33, 1332.e1, 10.1016/j.ajem.2015.03.019 Reddy, 2015, Transfusion-related acute lung injury after IVIG for myasthenic crisis, Neurocrit Care, 23, 259, 10.1007/s12028-015-0115-z Attard, 2015, Paradoxical response to intravenous immunoglobulin in a case of Parvovirus B19-associated chronic fatigue syndrome, J Clin Virol, 62, 54, 10.1016/j.jcv.2014.11.021 Kissel, 2015, Hypertension during intravenous immune globulin infusion for Kawasaki's disease: an underreported phenomenon?, Clin Pediatr (Phila), 54, 491, 10.1177/0009922814536776 Ammann, 2016, Intravenous immune globulin and thromboembolic adverse events in patients with hematologic malignancy, Blood, 127, 200, 10.1182/blood-2015-05-647552 Flannery, 2015, Deep venous thrombosis with pulmonary embolism related to IVIG treatment: a case report and literature review, Case Rep Med, 2015, 971321, 10.1155/2015/971321 Yu, 2016, Acute pulmonary embolism caused by highly aggregated intravenous immunoglobulin, Vox Sang, 110, 27, 10.1111/vox.12307 Dorwart, 2015, IVIG and graft coronary artery disease: a potentially deadly combination in pediatric heart transplant recipients, Pediatr Transplant, 19, 130, 10.1111/petr.12377 Tufekci, 2015, Cardiac rhythm abnormalities during intravenous immunoglobulin G (IVIG) infusion in two newborn infants: coincidence or association?, Clin Case Rep, 3, 731, 10.1002/ccr3.329 Thornby, 2015, Evidence-based strategies to reduce intravenous immunoglobulin-induced headaches, Ann Pharmacother, 49, 715, 10.1177/1060028015576362 Luban, 2015, Intravenous immunoglobulin-related hemolysis in patients treated for Kawasaki disease, Transfusion, 55, S90, 10.1111/trf.13089 Christensen, 2015, Increased hemolysis after administering intravenous immunoglobulin to a neonate with erythroblastosis fetalis due to Rh hemolytic disease, Transfusion, 55, 1365, 10.1111/trf.13104 Berg, 2015, Hemolytic events associated with intravenous immune globulin therapy: a qualitative analysis of 263 cases reported to four manufacturers between 2003 and 2012, Transfusion, 55, S36, 10.1111/trf.13198 Padmore, 2015, Possible mechanisms for intravenous immunoglobulin-associated hemolysis: clues obtained from review of clinical case reports, Transfusion, 55, S59, 10.1111/trf.13090 Scott, 2015, Hemolytic adverse events with immune globulin products: product factors and patient risks, Transfusion, 55, S2, 10.1111/trf.13148 Berg, 2015, Hemolytic events after the administration of lyophilized versus liquid immune globulin: an analysis of a single manufacturer's safety database, Transfusion, 55, 1847, 10.1111/trf.13105 Buehler, 2015, Is there evidence for recommending specific intravenous immunoglobulin formulations? A systematic review of head-to-head randomized controlled trials, Eur J Pharmacol, 747, 96, 10.1016/j.ejphar.2014.11.033 Rappold, 2015, Comparison of high-dose intravenous immunoglobulin (IVIG) in a 5% and a 10% solution does not reveal a significantly different spectrum of side-effects, J Eur Acad Dermatol Venereol, 10.1111/jdv.13496 Vultaggio, 2015, Subcutaneous immunoglobulin replacement therapy in patients with primary immunodeficiency in routine clinical practice: the VISPO prospective multicenter study, Clin Drug Investig, 35, 179, 10.1007/s40261-015-0270-1 Markvardsen, 2015, Heacache and nausea after treatment with high-dose subcutaneous versus intravenous immunoglobulin, Basic Clin Pharmacol Toxicol, 117, 409, 10.1111/bcpt.12428 Niebur, 2015, Efficacy and tolerability of 16% subcutaneous immunoglobulin compared with 20% subcutaneous immunoglobulin in primary antibody deficiency, Clin Exp Immunol, 181, 441, 10.1111/cei.12623 Hadden, 2015, Switch from intravenous to subcutaneous immunoglobulin in CIDP and MMN: improved tolerability and patient satisfaction, Ther Adv Neurol Disord, 8, 14, 10.1177/1756285614563056 Cherin, 2016, Long-term subcutaneous immunoglobulin use in inflammatory myopathies: a retrospective review of 19 cases, Autoimmun Rev, 15, 281, 10.1016/j.autrev.2015.12.003 Jain, 2015, Guidelines for the management of a pregnant trauma patient, J Obstet Gynaecol Can, 37, 553, 10.1016/S1701-2163(15)30232-2 McBain, 2015, Anti-D administration in pregnancy for preventing Rhesus alloimmunisation, Cochrane Database Syst Rev, 3, 9 Aitken, 2015, RhoD immune globulin products for prevention of alloimmunization during pregnancy, Am J Health Syst Pharm, 72, 267, 10.2146/ajhp140288 Pham, 2015, Rhesus immune globulin dosing in the obesity epidemic era, Arch Pathol Lab Med, 139, 1084, 10.5858/arpa.2014-0605-LE Solomon, 2015, Safety of fibrinogen concentrate: analysis of more than 27 years of pharmacovigilance data, Thromb Haemost, 113, 759, 10.1160/TH14-06-0514 Aawar, 2015, Fibrinogen concentrate versus placebo for treatment of postpartum haemorrhage: study protocol for a randomized controlled trial, Trials, 16, 1 Wasilko, 2015, Topical hemostatic agents and their role in upper extremity surgery, J Hand Surg Am, 40, 602, 10.1016/j.jhsa.2014.10.013 Karimi, 2015, Efficacy and safety of recombinant factor VII as rescue for severe perioperative bleeding in heartmate II recipients, J Card Surg, 30, 500, 10.1111/jocs.12555 Matino, 2015, Recombinant factor VIIa concentrate versus plasma-derived concentrates for treating acute bleeding episodes in people with haemophilia and inhibitors, Cochrane Database Syst Rev, 12, CD004449 Peyvandi, 2016, The past and future of haemophilia: diagnosis, treatments and its complications, Lancet, 388, 187, 10.1016/S0140-6736(15)01123-X Carcao, 2016, The role of previously untreated patient studies in understanding the development of FVIII inhibitors, Haemophilia, 22, 22, 10.1111/hae.12790 2015, Eloctate for hemophilia A, Med Lett Drugs Ther, 57, 143 Nathwani, 2014, Long term safety and efficacy of factor IX gene therapy in hemophilia B, N Engl J Med, 371, 1994, 10.1056/NEJMoa1407309 Cappabianca, 2016, Safety and efficacy of prothrombin complex concentrate as first-line treatment in bleeding after cardiac surgery, Crit Care, 20, 5, 10.1186/s13054-015-1172-6 Farsad, 2015, Comparison between PCC and FFP for the urgent reversal of warfarin in patients with mechanical heart valve in a tertiary care cardiac center, Iran J Pharm Res, 14, 877 Johansen, 2015, Prothrombin complex concentrate for reversal of vitamin K antagonist treatment in bleeding and non-bleeding patients, Cochrane Database Syst Rev, 7, CD010555 FDA News Release, 2015 Zheng, 2015, ADAMTS13 and von Willebrand factor in thrombotic thrombocytopenic purpura, Annu Rev Med, 66, 211, 10.1146/annurev-med-061813-013241 Wilhelm-Lee, 2015, Mortality risk of darbepoetin alfa versus epoetin alfa in patients with CKD: systematic review and meta-analysis, Am J Kidney Dis, 66, 69, 10.1053/j.ajkd.2014.12.012 Lindguist, 2015, Use of erythropoiesis-stimulating agents in the treatment of anemia in patients with systolic heart failure, J Cardiovasc Pharm Ther, 20, 59, 10.1177/1074248414541841 Mastromarino, 2014, Erythropoietin in cardiac disease: effective or harmful?, J Cardiovasc Med, 14, 870, 10.2459/JCM.0b013e328362c6ae Vlachopanos, 2015, Perioperative administration of high-dose recombinant human erythropoietin for delayed graft function prevention in kidney transplantation: a meta-analysis, Transpl Int, 28, 330, 10.1111/tri.12506 Mauricette, 2016, Biosimilar epoetin zeta in oncology and haematology: development and experience following 6 years of use, Acta Haematol, 135, 44, 10.1159/000438976 Merli, 2015, Eltrombopag for the treatment of thrombocytopenia-associated disorders, Expert Opin Pharmacother, 16, 2243, 10.1517/14656566.2015.1085512 Brierley, 2015, Thrombopoiesis-stimulating agents and the myelodysplastic syndromes, Br J Haematol, 169, 309, 10.1111/bjh.13285 Grainger, 2015, Eltrombopag for children with chronic immune thrombocytopenia (PETIT2): a randomized, multicenter, placebo-controlled trial, Lancet, 386, 1649, 10.1016/S0140-6736(15)61107-2 Kowalczk, 2015, Initial experience with the use of thrombopoetin receptor agonists in patients with refractory HIV-associated immune thrombocytopenic purpura: a case series, J Int Assoc Provid AIDS Care, 14, 211, 10.1177/2325957414557266 Gonzales-Porras, 2015, Use of eltrombopag after romiplostim in primary immune thrombocytopenia, Br J Haematol, 169, 111, 10.1111/bjh.13266 Michel, 2015, Efficacy and safety of the thrombopoietin receptor agonist romiplostim in patients aged >65 with immune thrombocytopenia, Ann Hematol, 94, 1973, 10.1007/s00277-015-2485-x Choe, 2015, Severe romiplostim-induced rebound thrombocytopenia after splenectomy for refractory ITP, Ann Pharmacother, 49, 140, 10.1177/1060028014555540 Marshall, 2015, Romiplostim in the management of the thrombocytopenic surgical patient, Transfusion, 55, 2505, 10.1111/trf.13181 Selleslag, 2015, Impact of self-administration of romiplostim by patient with chronic immune thrombocytopenia compare with administration by healthcare provided, Eur J Haematol, 94, 169, 10.1111/ejh.12415 Lafeuillade, 2015, Residual risk and retrospective analysis of transfusion-transmitted bacterial infection reported by the French national hemovigilance network from 2000 to 2008, Transfusion, 55, 636, 10.1111/trf.12883 Kou, 2015, Fatal false-negative transfusion infection involving a buffy coat platelet pool contaminated with biofilm-positive Staphylococcus epidermidis: a case report, Transfusion, 55, 2384, 10.1111/trf.13154 Arellanos-Soto, 2015, Constant risk of dengue virus infection by blood transfusion in an endemic area in Mexico, Transfus Med, 25, 122, 10.1111/tme.12198 Oh, 2015, Bitten by a bug or a bag? Transfusion-transmitted dengue: a rare complication in the bleeding surgical patient, Transfusion, 55, 1655, 10.1111/trf.13054 Fuse, 2015, Late onset post-transfusion hepatitis E developing during chemotherapy for acute promyelocytic leukemia, Intern Med, 54, 657, 10.2169/internalmedicine.54.2332 Sayani, 2015, Hepatitis E infection in a patient with transfusion-dependent β thalassemia, Am J Hematol, 90, E50, 10.1002/ajh.23905 Mosesso, 2015, Adverse late and long-term treatment effects in adult allogeneic hematopoietic stem cell transplant survivors, Am J Nurs, 115, 22, 10.1097/01.NAJ.0000473311.79453.64 Arai, 2015, Increasing incidence of chronic graft-versus-host disease in allogeneic transplantation: a report from the Center for International Blood and Marrow Transplant Research, Biol Blood Marrow Transplant, 21, 266, 10.1016/j.bbmt.2014.10.021 Ruzhansky, 2015, Neuromuscular complications of hematopoietic stem cell transplantation, Muscle Nerve, 52, 480, 10.1002/mus.24724 Sag, 2015, Hyperthyroidism after allogeneic hematopoietic stem cell transplantation: a report of four cases, J Clin Res Pediatr Endocrinol, 7, 349, 10.4274/jcrpe.2295 Horwitz, 2015, Incidence and risk factors for cataract after haematopoietic stem cell transplantation for childhood leukaemia: an LEA study, Br J Haematol, 168, 518, 10.1111/bjh.13148 Kim, 2015, Hematopoietic stem cell transplant-associated thrombotic microangiopathy: review of pharmacologic treatment options, Transfusion, 55, 452, 10.1111/trf.12859 Dandoy, 2015, Abnormal echocardiography 7 days after stem cell transplantation may be an early indicator of thrombotic microangiopathy, Biol Blood Marrow Transplant, 21, 113, 10.1016/j.bbmt.2014.09.028 Wang, 2015, Autoimmune hemolytic anemia after allogeneic hematopoietic stem cell transplantation: analysis of 533 adult patients who underwent transplantation at King's College Hospital, Biol Blood Marrow Transplant, 21, 60, 10.1016/j.bbmt.2014.09.009 Norvell, 2015, Liver disease after hematopoietic cell transplantation in adults, Transplant Rev (Orlando), 29, 8, 10.1016/j.trre.2014.08.001 Seifert, 2015, Heparanase polymorphisms: influence on incidence of hepatic sinusoidal obstruction syndrome in children undergoing allogeneic hematopoietic stem cell transplantation, J Cancer Res Clin Oncol, 141, 877, 10.1007/s00432-014-1857-2 Mathur, 2016, Atrial fibrillation in hematologic malignancies, especially after autologous hematopoietic stem cell transplantation: review of risk factors, current management, and future directions, Clin Lymphoma Myeloma Leuk, 16, 70, 10.1016/j.clml.2015.10.001 Genberg, 2015, Cardiac function after hematopoietic cell transplantation: an echocardiographic cross-sectional study in young adults treated in childhood, Pediatr Blood Cancer, 62, 143, 10.1002/pbc.25135 Paulson, 2015, Routine filtration of hematopoietic stem cell products: the time has arrived, Transfusion, 55, 1980, 10.1111/trf.13169